Verley $38M Series A for Precision Fermentation Protein

Lyon-based Verley, a pioneering force in sustainable nutrition, has successfully closed an oversubscribed Series A funding round, securing a substantial $38 million. This significant capital injection is poised to propel the company's ambitious plans for industrial expansion and market penetration, particularly for its advanced whey protein ingredients developed through precision fermentation.

The global protein market is experiencing unprecedented growth, projected to reach an impressive $31.8 billion by 2025. This surge is driven by a confluence of factors, including evolving dietary preferences, a burgeoning health and wellness trend, and the increasing adoption of GLP-1 treatments, which saw one in eight U.S. adults utilizing them in 2025. Traditional dairy production struggles to meet this escalating demand sustainably, facing environmental constraints and supply chain pressures. This creates a critical void that innovative solutions like Verley's are uniquely positioned to fill, offering high-quality, digestible protein alternatives with a significantly reduced ecological footprint.

Verley's proprietary approach focuses on producing beta-lactoglobulin (BLG), a key functional whey protein, using precision fermentation. Marketed under the FermWhey™ range, these ingredients are engineered for superior performance in diverse food and nutrition applications, from protein shots to ready-to-drink beverages. Their attributes, including high purity, enhanced solubility, emulsification, and gelling properties, address specific industrial requirements, enabling manufacturers to develop clean-label, high-protein products that resonate with modern consumer demands for both nutrition and sustainability.

The company's rapid progress from inception to industrial readiness has been a key factor in attracting investor confidence. In less than four years, Verley has achieved critical regulatory milestones, including a self-affirmed GRAS (Generally Recognized As Safe) status in 2024, followed by a coveted FDA "No Questions" letter in 2025 for the U.S. market. This regulatory clearance, coupled with a robust intellectual property portfolio spanning fermentation and protein functionalization technologies, underscores the de-risked nature of Verley's proposition and its readiness for commercial scale.

The $38 million Series A round saw strong participation from both new and existing investors. Leading the round was Alven, joined by new participants Blast and Bpifrance. Returning investors include Sofinnova Partners, Sparkfood, Captech, and Founders Future. Additionally, Bpifrance provided crucial non-dilutive support. This collective backing will primarily fund Verley's strategic entry into the U.S. market, facilitating commercial deployment and initial customer scale-up, alongside a significant ramp-up of production capacities. Further investment in research and development will continue to enhance the performance and sustainability of its core technologies.

This funding not only validates Verley's technological prowess but also highlights Europe's growing leadership in advanced food technology. By building scalable, sustainable protein production capabilities, Verley contributes to strengthening food sovereignty and resilience in a global market increasingly susceptible to supply chain disruptions. Following its U.S. launch, the company plans to expand into Europe and the Middle East, reinforcing its global ambitions and cementing its role in shaping the future of nutrition.